KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to $11.0 billion.

  • Bristol Myers Squibb's Operating Expenses fell 932.85% to $11.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $38.9 billion, marking a year-over-year decrease of 3142.79%. This contributed to the annual value of $38.9 billion for FY2025, which is 3142.79% down from last year.
  • As of Q4 2025, Bristol Myers Squibb's Operating Expenses stood at $11.0 billion, which was down 932.85% from $9.1 billion recorded in Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's Operating Expenses peaked at $23.4 billion during Q1 2024, and registered a low of $8.2 billion during Q1 2025.
  • For the 5-year period, Bristol Myers Squibb's Operating Expenses averaged around $10.4 billion, with its median value being $9.9 billion (2022).
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 17291.93% in 2024, then plummeted by 6480.05% in 2025.
  • Bristol Myers Squibb's Operating Expenses (Quarter) stood at $10.1 billion in 2021, then decreased by 5.73% to $9.5 billion in 2022, then increased by 2.68% to $9.8 billion in 2023, then grew by 24.12% to $12.2 billion in 2024, then fell by 9.33% to $11.0 billion in 2025.
  • Its Operating Expenses stands at $11.0 billion for Q4 2025, versus $9.1 billion for Q3 2025 and $10.5 billion for Q2 2025.